arrow
W

Wah-Kheong Chan

University of Malaya
H指数:51
被引数:1.7万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

The Malaysian Society of Gastroenterology and Hepatology Consensus Statements on Prevention and Early Detection of Hepatocellular Carcinoma in Malaysia

马来西亚胃肠病学和肝病学学会关于马来西亚肝癌预防和早期检测的共识声明

2026-09-070
OAAI
Delphi survey to explore core curriculum for training the next generation of hepatologists

德尔菲调查探索下一代肝病学家培训的核心课程

2026-08-010
PRE
Physician Perspectives on Hepatitis C Treatment During Pregnancy: A Multinational Multispecialty Survey

妊娠期丙型肝炎治疗:医师观点——一项跨国多专科调查

2026-04-060
PRE
Histological severity and hepatic outcomes in patients with metabolic dysfunction-associated steatotic liver disease and discrepant FIB-4 and liver stiffness measurement

代谢功能障碍相关脂肪性肝病且FIB-4与肝硬度测量结果不一致患者的组织学严重程度和肝脏结局

2026-01-011
PRE
New CLA3+/4 scores predict outcomes in MASLD

新CLA3+/4评分可预测MASLD的结局

2026-01-010
OA
Cardiovascular-kidney-metabolic syndrome and the risk of liver fibrosis progression and liver-related events in MASLD

心血管-肾脏-代谢综合征与MASLD患者肝纤维化进展及肝脏相关事件的风险

2025-12-010
PRE
Variations in Estimated Glomerular Filtration Rate Across Countries in Patients With Metabolic Dysfunction-Associated Steatotic Liver Disease and Their Association With Liver Fibrosis: A Multicenter Study

代谢功能障碍相关脂肪性肝病患者的估算肾小球滤过率在国家间的差异及其与肝纤维化的关联:一项多中心研究

MEDCOMM
IF10.7
2025-11-240
OAAI
Predictors of fibrosis, clinical events and mortality in MASLD: Data from the Global-MASLD study

Younossi, Z.M.; de Avila, L.; Petta, S.; Hagström, H.; Kim, S.U.; Nakajima, A.; Crespo, J.; Castera, L.; Alkhouri, N.; Zheng, M.H.; 等. MASLD的纤维化、临床事件及死亡率的预测因素:全球MASLD研究的数据. 肝病学 2025. [Google Scholar] [CrossRef]

2025-11-013
PRE
Long-Term Glycemic Control and the Risk of Liver Stiffness Progression and Liver-Related Events in MASLD

长期血糖控制与肝硬度进展及肝脏相关事件风险的关系 (MASLD)

2025-10-100
PRE
A multinational survey of physician knowledge about management of chronic hepatitis C

关于慢性丙型肝炎管理知识的医师跨国调查

2025-10-020
OAAI
Global, Regional, and National Burden of Primary Liver Cancer Attributable to Metabolic Risks: An Analysis of the Global Burden of Disease Study 1990-2021

可归因于代谢风险的原发性肝癌的全球,区域和国家负担: 对1990-2021全球疾病负担研究的分析

2025-10-017
PRE
Association between longitudinal weight change and clinical outcome in individuals with MASLD

MASLD个体中纵向体重变化与临床结局的关联

2025-10-012
PRE
Global performance of non-invasive tests in MASLD: Insights from the G-MASLD study

非侵入性试验在MASLD中的全球表现:G-MASLD研究的见解

2025-10-010
PRE
Effect of Hypertension on Long-term Adverse Clinical Outcomes and Liver Fibrosis Progression in MASLD

高血压对长期不良临床结局及MASLD患者肝纤维化进展的影响

2025-08-230
PRE
Longitudinal Changes in Fibrosis Markers: Monitoring Stiffness/Fibrosis Progression and Prognostic Outcomes in MASLD

纤维化标志物的纵向变化:监测MASLD的僵硬/纤维化进展和预后结局

2025-07-240
PRE
A novel risk prediction model for hepatocellular carcinoma in MASLD: A multinational, multicenter cohort study

一种新型MASLD相关肝细胞癌风险预测模型:一项跨国、多中心队列研究

2025-07-100
PRE
Effect of Antidiabetic Drug Classes on the Risk of Liver-Related Events in Individuals With T2D and MASLD

Shi, Y.; Kim, S.U.; Yip, T.C.; Tsochatzis, E.; Petta, S.; Nakajima, A.; Hagström, H.; Bugianesi, E.; Chan, W.K.; Boursier, J.; 等. 抗糖尿病药物类别对T2D和MASLD患者肝脏相关事件风险的影响. Clin. Gastroenterol. Hepatol. Off. Clin. Pract. J. Am. Gastroenterol. Assoc. 2025; advance online publication. [Google Scholar] [CrossRef]

2025-06-070
PRE
The prevalence of metabolic syndrome and the associated factors in a multiethnic upper-middle-income country in Asia: findings from a nationwide community-based study in 2023

代谢综合征的患病率及其相关因素:一项在亚洲多民族中高收入国家开展的全国性社区研究2023年结果

2025-04-220
OA
Global Burden of Major Chronic Liver Diseases in 2021

全球主要慢性肝病负担2021年

2025-04-010
PRE